• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Certara’s d3 Medicine, Australian Department of Defence partner

Certara’s d3 Medicine, Australian Department of Defence partner

April 5, 2017
CenterWatch Staff

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced that its d3 Medicine company has been selected to conduct a national audit of Australia’s medical countermeasures (MCM) product research and development (R&D) capabilities and capacity.

MCM include vaccines, therapeutics and diagnostics against chemical, biological and radiological threats; emerging infectious diseases; and pandemics.

DST Group is partnering with d3 Medicine to assess and then optimize Australia’s MCM research, development and manufacturing capabilities.

“Thorough preparation is the best way to prevent a health crisis becoming a disaster,” said d3 Medicine President Craig R. Rayner, PharmD, MBA. “We are proud to help the Australian Government develop this comprehensive MCM preparedness approach, which is considered a priority under the Defence White Paper 2016.”

This new activity builds upon an initial audit conducted by d3 Medicine and DST Group in 2012. It aims to assess the nation’s current level of MCM knowledge, research, products, infrastructure and capability in both industry and academia.

d3 Medicine and DST Group continue to enhance their previously successful interactions. Together they have coordinated war gaming exercises with the Australian R&D community; proposed product development strategies for emergency situations; and collaborated with the Therapeutic Goods Administration to understand how an MCM emergency could inform the review and use of a MCM diagnostic and therapeutic solution.

d3 Medicine is well positioned to support the activities of DST Group. The company’s extensive global expertise in PK/PD modelling, pharmacometrics, asset due diligence, regulatory proficiency and clinical trials design are critical to the strategic guidance of this new initiative.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing